These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 18691131)

  • 1. Serotonin 5-HT6 receptor antagonists for the treatment of Alzheimer's disease.
    Geldenhuys WJ; Van der Schyf CJ
    Curr Top Med Chem; 2008; 8(12):1035-48. PubMed ID: 18691131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemical update on the potential for serotonin 5-HT
    Kucwaj-Brysz K; Baltrukevich H; Czarnota K; Handzlik J
    Bioorg Med Chem Lett; 2021 Oct; 49():128275. PubMed ID: 34311086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medicinal chemistry strategies to 5-HT(6) receptor ligands as potential cognitive enhancers and antiobesity agents.
    Holenz J; Pauwels PJ; Díaz JL; Mercè R; Codony X; Buschmann H
    Drug Discov Today; 2006 Apr; 11(7-8):283-99. PubMed ID: 16580970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The serotonin 5-HT6 receptor: a viable drug target for treating cognitive deficits in Alzheimer's disease.
    Geldenhuys WJ; Van der Schyf CJ
    Expert Rev Neurother; 2009 Jul; 9(7):1073-85. PubMed ID: 19589055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serotonin 5-HT6 receptor antagonists for the treatment of cognitive deficiency in Alzheimer's disease.
    Benhamú B; Martín-Fontecha M; Vázquez-Villa H; Pardo L; López-Rodríguez ML
    J Med Chem; 2014 Sep; 57(17):7160-81. PubMed ID: 24850589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 5-HT6 receptor antagonists as potential therapeutics for cognitive impairment.
    Rossé G; Schaffhauser H
    Curr Top Med Chem; 2010; 10(2):207-21. PubMed ID: 20166958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serotonin 5-HT
    Ferrero H; Solas M; Francis PT; Ramirez MJ
    CNS Drugs; 2017 Jan; 31(1):19-32. PubMed ID: 27914038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progress in Investigational Agents Targeting Serotonin-6 Receptors for the Treatment of Brain Disorders.
    Nirogi R; Jayarajan P; Shinde A; Mohammed AR; Grandhi VR; Benade V; Goyal VK; Abraham R; Jasti V; Cummings J
    Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serotonin: A New Hope in Alzheimer's Disease?
    Claeysen S; Bockaert J; Giannoni P
    ACS Chem Neurosci; 2015 Jul; 6(7):940-3. PubMed ID: 26011650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of 5 HT6-receptor antagonists in Alzheimer's disease: an update.
    Khoury R; Grysman N; Gold J; Patel K; Grossberg GT
    Expert Opin Investig Drugs; 2018 Jun; 27(6):523-533. PubMed ID: 29848076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging chemical therapies targeting 5-hydroxytryptamine in the treatment of Alzheimer's disease.
    Calhoun A; Ko J; Grossberg GT
    Expert Opin Emerg Drugs; 2017 Mar; 22(1):101-105. PubMed ID: 28253832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serotonergic 5-HT6 Receptor Antagonists: Heterocyclic Chemistry and Potential Therapeutic Significance.
    Bali A; Singh S
    Curr Top Med Chem; 2015; 15(17):1643-62. PubMed ID: 25915615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting biological activity and design of 5-HT
    de Sousa DS; da Silva AP; Chiari LPA; de Angelo RM; de Sousa AG; Honorio KM; da Silva ABF
    J Mol Model; 2024 Sep; 30(10):350. PubMed ID: 39325274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulating 5-HT
    Lalut J; Karila D; Dallemagne P; Rochais C
    Future Med Chem; 2017 May; 9(8):781-795. PubMed ID: 28504917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antagonism of the 5-HT
    de Jong IEM; Mørk A
    Neuropharmacology; 2017 Oct; 125():50-63. PubMed ID: 28711518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AVN-492, A Novel Highly Selective 5-HT6R Antagonist: Preclinical Evaluation.
    Ivachtchenko AV; Okun I; Aladinskiy V; Ivanenkov Y; Koryakova A; Karapetyan R; Mitkin O; Salimov R; Ivashchenko A
    J Alzheimers Dis; 2017; 58(4):1043-1063. PubMed ID: 28550249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual-acting agents for improving cognition and real-world function in Alzheimer's disease: Focus on 5-HT6 and D3 receptors as hubs.
    Millan MJ; Dekeyne A; Gobert A; Brocco M; Mannoury la Cour C; Ortuno JC; Watson D; Fone KCF
    Neuropharmacology; 2020 Oct; 177():108099. PubMed ID: 32525060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigational drugs targeting 5-HT6 receptors for the treatment of Alzheimer's disease.
    Wicke K; Haupt A; Bespalov A
    Expert Opin Investig Drugs; 2015; 24(12):1515-28. PubMed ID: 26548316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis, and pharmacological evaluation of multitarget-directed ligands with both serotonergic subtype 4 receptor (5-HT4R) partial agonist and 5-HT6R antagonist activities, as potential treatment of Alzheimer's disease.
    Yahiaoui S; Hamidouche K; Ballandonne C; Davis A; de Oliveira Santos JS; Freret T; Boulouard M; Rochais C; Dallemagne P
    Eur J Med Chem; 2016 Oct; 121():283-293. PubMed ID: 27266998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemocentric informatics approach to drug discovery: identification and experimental validation of selective estrogen receptor modulators as ligands of 5-hydroxytryptamine-6 receptors and as potential cognition enhancers.
    Hajjo R; Setola V; Roth BL; Tropsha A
    J Med Chem; 2012 Jun; 55(12):5704-19. PubMed ID: 22537153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.